News und Analysen
DGAP-News: Elmos Semiconductor SE: Sale of wafer fab in Dortmund to the MEMS foundry Silex Microsystems AB - Long-term supply agreement until at least 2027 signed
AIXTRON says YESvGaN / Epitaxy specialist AIXTRON is partner of EU research project YESvGaN / High energy efficiency and low CO2 emissions by using GaN power transistors
AIXTRON sagt YESvGaN / Epitaxie-Spezialist AIXTRON ist Partner im EU-Forschungsprojekt YESvGaN / Hohe Energieeffizienz und niedrige CO2-Emissionen durch GaN-Leistungstransistoren
DGAP-News: Vossloh Aktiengesellschaft: Vossloh wins another major order from China for rail fastening systems
DGAP-News: Vossloh Aktiengesellschaft: Vossloh gewinnt erneut Großauftrag für Schienenbefestigungssysteme in China
2CRSi SA awarded new contract by EdgeMode. EdgeMode significantly increases mining and HPC capacity through additional green high-performance servers.
Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in January 2022
POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
DGAP-News: Nordex SE: Nordex Group erhält Auftrag über 196 MW von Swift Current Energy aus den USA
DGAP-News: Nordex SE: Swift Current Energy Secures 196 MW in Wind Turbine Supply from Nordex Group
DGAP-News: Biotest AG: Biotest treats first CMV-positive pregnant woman in Phase III clinical trial to prevent transmission of CMV infection to the unborn child
DGAP-News: Biotest AG: Biotest behandelt erste CMV-positive Schwangere in klinischer Phase III-Studie zur Prävention einer Übertragung der CMV-Infektion auf das ungeborene Kind
Perion Network Announces Closing of $180.0 Million Follow-on Offering of Ordinary Shares, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Perion Network Ltd. (NASDAQ: PERI), a global advertising technology company that delivers holistic solutions across the three main pillars of digital advertising – ad search, social media and
GeNeuro erhält von der Schweizer Regierung Finanzmittel in Höhe von 6,7 Millionen Schweizer Franken (6,4 Millionen Euro) für die Entwicklung von Temelimab gegen Long COVID
GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), ein biopharmazeutisches Unternehmen, das neue Therapien für neurodegenerative und Autoimmunerkrankungen entwickelt, meldete heute, dass
Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Für neun von zehn Versicherern in Europa ist bessere Kundenerfahrung Top-Treiber der digitalen Transformation
Die Nachfrage nach besseren Kundenerlebnissen ist der Haupttreiber für die digitale Transformation in der europäischen Versicherungswirtschaft. Doch parallel zum Fortgang der Digitalisierung nehmen
Nine in 10 Insurance Leaders in Europe Say Customer Experience is the Top Driver of Digital Transformation
Demand for improved customer experience is the top driver of digital transformation in Europe’s insurance industry, but with growing digitalization, insurers report increasing security
Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc
RRD Board Unanimously Determines that Chatham’s Unsolicited Proposal to Acquire RRD for $10.85 Per Share in Cash Constitutes a “Superior Proposal”
R.R. Donnelley & Sons Company (NYSE: RRD) (“RRD” or the “Company”) announced today that its Board of Directors (the “Board”) unanimously determined that an unsolicited proposal from Chatham Asset
Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented an update from its Phase II SUMMIT trial at the ongoing 2021 San Antonio Breast Cancer Symposium (SABCS) Annual
Victory Capital Reports November 2021 Assets Under Management
Victory Capital Holdings, Inc. (NASDAQ: VCTR) (“Victory Capital” or the “Company”) today reported assets under management (AUM) of $160.5 billion as of November 30, 2021.
Victory Capital
DGAP-News: RIB Software SE (RIB) unterzeichnet einen Phase-II-Auftrag (Nr. 46 / 2021) mit der DEGES